tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2024 Jan-Dec;23(1):88-101.
doi: 10.1080/14760584.2023.2293241. Epub 2023 Dec 15. Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity
Laura Colombo[SUP] 1 [/SUP], Sanjay Hadigal[SUP] 2 [/SUP], Jos Nauta[SUP] 3 [/SUP], Alona Kondratenko[SUP] 4 [/SUP], Jutta Rogoll[SUP] 5 [/SUP], Serge Van de Witte[SUP] 3 [/SUP]
Affiliations
Introduction: This paper summarizes the safety and immunogenicity data of Influvac Tetra across all age groups starting from 6 months of age, obtained during its clinical development program.
Areas covered: The article covers the clinical development program of Influvac Tetra based on five registration studies that included different age groups, different comparators, and participants from Europe and Asia. Safety and immunogenicity were assessed in all studies and in one study, the efficacy of Influvac Tetra was assessed.
Expert opinion: Seasonal influenza is a vaccine-preventable disease that can cause serious complications. Several types of influenza vaccines are available, including egg-based (standard dose, high dose, and adjuvanted), cell-based, and recombinant. The COVID-19 pandemic has stimulated innovation in the development such as mRNA vaccines. However, these vaccines are still in development and the true value still has to be proven. Regardless of the type of vaccine, it is also important to increase overall vaccination coverage. ECDC recommends that EU Member States implement action plans and policies aimed at reaching 75% coverage in at-risk groups and healthcare workers. Even so, vaccine coverage is still far from recommended.
Keywords: Influvac Tetra; egg-based vaccine; immunogenicity; influenza; reactogenicity; safety; subunit vaccine; tetravalent.
. 2024 Jan-Dec;23(1):88-101.
doi: 10.1080/14760584.2023.2293241. Epub 2023 Dec 15. Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity
Laura Colombo[SUP] 1 [/SUP], Sanjay Hadigal[SUP] 2 [/SUP], Jos Nauta[SUP] 3 [/SUP], Alona Kondratenko[SUP] 4 [/SUP], Jutta Rogoll[SUP] 5 [/SUP], Serge Van de Witte[SUP] 3 [/SUP]
Affiliations
- PMID: 38088157
- DOI: 10.1080/14760584.2023.2293241
Introduction: This paper summarizes the safety and immunogenicity data of Influvac Tetra across all age groups starting from 6 months of age, obtained during its clinical development program.
Areas covered: The article covers the clinical development program of Influvac Tetra based on five registration studies that included different age groups, different comparators, and participants from Europe and Asia. Safety and immunogenicity were assessed in all studies and in one study, the efficacy of Influvac Tetra was assessed.
Expert opinion: Seasonal influenza is a vaccine-preventable disease that can cause serious complications. Several types of influenza vaccines are available, including egg-based (standard dose, high dose, and adjuvanted), cell-based, and recombinant. The COVID-19 pandemic has stimulated innovation in the development such as mRNA vaccines. However, these vaccines are still in development and the true value still has to be proven. Regardless of the type of vaccine, it is also important to increase overall vaccination coverage. ECDC recommends that EU Member States implement action plans and policies aimed at reaching 75% coverage in at-risk groups and healthcare workers. Even so, vaccine coverage is still far from recommended.
Keywords: Influvac Tetra; egg-based vaccine; immunogenicity; influenza; reactogenicity; safety; subunit vaccine; tetravalent.